Iambic Therapeutics Files Initial S-1 for Nasdaq IPO
Iambic Therapeutics, Inc. (SEC file no. 0001997038) filed its initial S-1 registration statement on September 21, 2026 (57 MB). The biotech focuses on targeted protein degradation; all programs are preclinical or Phase I, with no approved products or revenue.
51CFO view：First-time biotech S-1 demands CFO expertise in R&D capitalization policy, clinical trial cost allocation, stock-based compensation modeling, and ‘cash runway’ disclosure under SEC Compliance & Disclosure Interpretations. Must justify non-GAAP metrics (e.g., cash burn per program) to underwriters and SEC staff.
Iambic Therapeutics, Inc. (SEC file no. 0001997038) filed its initial S-1 registration statement on September 21, 2026 (57 MB). The biotech focuses on targeted protein degradation; all programs are preclinical or Phase I, with no approved products or revenue.
Source：SEC EDGAR · S-1 招股书备案
Why this matters to your CFO search
Where this touches your finance hire
Every listing event changes what you need from a CFO. Start from the step you are actually at.
What kind of CFO does a US IPO need?
S-1 / F-1 filing, US GAAP conversion, roadshow — the hard requirements.
Read →
Who owns SEC reporting and US GAAP?
Signature responsibility for 10-K / 10-Q / 8-K / 20-F, and common comments.
Read →
Who runs finance through a SPAC merger?
De-SPAC files F-1 / 424(b); merger audit and disclosure cadence differ.
Read →